|
|
|
| Webinar: Keeping Hope Alive: Transforming Rare Disease Drug Development for a Faster Cure | Join us on April 15th to explore how the rapid development of COVID vaccines sets a precedent for curative therapies for rare diseases. Learn how CDMOs expedite workflows, streamline manufacturing, and ensure reliable, scalable processes. Discover how supporting analytics and robust strategies accelerate the development, commercialization, and timely delivery of life-changing gene therapies. Click here to learn more. |
|
|
|
Optimizing Cell Therapy Development: Part 2 | Article | By Dr. Bruce Thompson, Kincell Bio | Plan early and align research, development, and commercial priorities to ensure a seamless transition from clinical development to scalable, cost-efficient commercialization. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Professionals in our development and manufacturing outsourcing ecosystem are worried about inadequate training – in-house at their biotechs, and at their CDMOs. A main concern is a lack of sufficiently trained personnel to perform the various technology transfers to keep our industry running efficiently. | |
|
|
The Costs Of Disengagement From China | By Outsourced Pharma Live | If we ever did implement (suffer through?) some rather large-scale “disengagement” between the U.S. and China in the biopharma industry realm, what costs would we incur? |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
Developing An mRNA-Encoded Antibody Platform To Accelerate Therapies | Poster | By Roxana Redis, Dan Rocca, Maria Blanca Torroba, Rachel Pooley, et al., Vernal Biosciences | In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing. |
|
|
|
|
Strategies For Engineering Mammalian Cells | Video | Applied StemCell | Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort. |
|
|
Navigating The Allogeneic Commercialization Journey | Article | FUJIFILM Diosynth Biotechnologies | Review the pivotal moments, challenges, triumphs, and lessons learned that have shaped an evolution from facility construction to a fully operational, patient-focused CDMO. |
|
|
|
|
|
Toxicity Studies | Aliri Bioanalysis | Utilizing statistical analysis and a proprietary metabolomics database, see how we detect and identify molecular toxicity markers, providing critical safety insights into potential drug candidates. |
|
|
What We Do | Ascend & ABL Inc. | From early pre-clinical phases into the clinic and out on the market, we understand that consistent product quality is not negotiable and work to get it right early on. |
|
|
Analytical Services And Quality | ElevateBio | Our robust analytical capabilities support development processes and ensure our products are well characterized, safe and meet regulatory guidelines. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
